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Introduction {#sec1}
============

The use of embryonic stem cells (ESCs) has been an invaluable tool for basic cell and biomedical research for more than two decades. The discovery of cellular reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) ([@bib21]) revolutionized the field of regenerative medicine. These iPSCs can be generated from patient material and subsequently differentiated into a desired cell type for allogenic or ideally autologous cell therapy. In addition, iPSC technology enabled disease-in-a-dish modeling, for example, to better understand monogenetic disorders or to perform drug screenings in a personalized manner.

In stem cells the maintenance of pluripotency and self-renewal are crucial processes necessary to retain the differentiation capacity into various cell types of the three germ layers. In addition to the core pluripotency factors Oct4, Sox2, and Nanog, chromatin- and RNA-mediated mechanisms are involved in the regulation of pluripotency, which are not yet fully understood ([@bib15]). During differentiation, pluripotency and developmental genes undergo various changes, including altered chromatin interactions, histone modifications, and subnuclear localization. This leads to a change in expression patterns of genes connected to pluripotency, features of stem cells, and differentiated cell types.

Another level of complexity in the regulation of pluripotency is added by non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNA. lncRNAs constitute the largest and most heterogeneous subclass of ncRNAs classified by a transcript length of over 200 nucleotides. They play crucial roles in many physiological and pathophysiological processes ([@bib4]) and regulate gene expression transcriptionally and post-transcriptionally by manifold mechanisms ([@bib2], [@bib19]). However, due to their large number (lncipedia.org currently annotates 56,946 human lncRNA genes) and diversity, lncRNA research is still in its infancy and many lncRNA-controlled processes remain elusive. Additional challenges for studying lncRNAs are their frequently low level of expression and relatively poor sequence conservation, even between closely related species.

In contrast, lncRNA *Cyrano* (*OIP5-AS1*) is both locus- and sequence-conserved with a high complementary miRNA-7 binding site in an ultra-conserved region ([@bib22]). *Cyrano* was first described in zebrafish embryogenesis, necessary for the development of eyes and brain ([@bib22]). In HeLa cells *Cyrano* acts as a sponge for the RNA-binding protein HuR which influences proliferation. If HuR is not sponged by *Cyrano*, it stabilizes its target mRNAs, which code for pro-proliferative proteins, such as cyclin A2 and D1 ([@bib13]). Apoptosis is regulated by *Cyrano* in vascular endothelial cells upon treatment with oxidative low-density lipoprotein ([@bib23]). Moreover, *Cyrano* is part of a regulatory network of ncRNAs, including miRNA-7 in murine brains ([@bib14]), and a regulatory role in pluripotency and self-renewal via miRNA-7 was proposed in murine ESCs ([@bib20]).

The high conservation of *Cyrano* between vertebrates and its stem cell-enriched expression suggested an important regulatory role of this lncRNA, which prompted us to generate *Cyrano* knockout (KO) iPSCs. Surprisingly, *Cyrano* was concurrently described as an essential lncRNA for the maintenance of pluripotency and self-renewal in ESCs ([@bib20]). Since this was in marked contrast to our results in *Cyrano* KO iPSCs, we decided to further investigate the specific role of *Cyrano* in pluripotency and self-renewal using different CRISPR/Cas9 and small interfering RNA (siRNA) approaches in murine and human PSCs.

Results {#sec2}
=======

*Cyrano* Is Highly Expressed in iPSCs {#sec2.1}
-------------------------------------

The remarkable species conservation prompted us to quantify *Cyrano* molecules in commonly used murine and human cell lines, as the expression of lncRNAs is often cell-type-specific ([@bib4]). A plasmid standard containing a sequence of the murine or human *Cyrano* transcript, respectively, was used for absolute quantification by qRT-PCR. Both human and murine *Cyrano* were strongly enriched in iPSCs compared with somatic cell lines ([Figures 1](#fig1){ref-type="fig"}A and 1B). RNA fluorescence in situ hybridization (FISH) with a *Cyrano*-specific probe followed by confocal microscopy and 3D reconstruction revealed a cytoplasmic localization in iPSCs ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}).Figure 1*Cyrano* Is Highly Enriched in iPSCsAbsolute quantification of murine (A) and human (B) *Cyrano* in different cell lines. qRT-PCR and a plasmid standard containing parts of murine or human *Cyrano* were used for quantification, n = 3 technical replicates. SVEC, seminal vesicle epithelial cells; RAW264.7 macrophages; HCF, human cardiac fibroblasts; iPSC-CM, iPSC-derived cardiomyocytes; HUVEC, human umbilical vein endothelial cells; macrophages, peripheral blood mononuclear cell-derived macrophages.(C) Representative RNA FISH images stained with a *Cyrano*-specific probe and phalloidin in unmodified human iPSCs as 3D reconstruction. Scale bar, 5 μm.

*Cyrano* Is Dispensable for Maintenance of Pluripotency in Murine iPSCs {#sec2.2}
-----------------------------------------------------------------------

To address the role of *Cyrano* in pluripotency, OG2 iPSCs (expressing a pOCT4-EGFP transgene) ([@bib12]) were used to generate *Cyrano* KO cells by a dual guide RNA (gRNA) CRISPR/Cas9 approach ([@bib11]) ([Figure 2](#fig2){ref-type="fig"}A). The gRNAs were designed to excise the first exon of *Cyrano*, including parts of the promoter ([Figure 2](#fig2){ref-type="fig"}B). The dual gRNA vector, which also carries a dTomato fluorescence marker, was transiently transfected into OG2 iPSCs. Transfected cells were sorted by FACS and seeded as single cells for clonal expansion. Homo- and heterozygous KO clones for both gRNA combinations were identified by PCR in genomic DNA ([Figure 2](#fig2){ref-type="fig"}C) and successful excision confirmed by Sanger sequencing ([Figure 2](#fig2){ref-type="fig"}D). One heterozygous and one homozygous KO clone were selected for further analysis which, as expected, showed a significant reduction or complete elimination of *Cyrano* RNA expression as determined by qRT-PCR ([Figure 2](#fig2){ref-type="fig"}E).Figure 2*Cyrano* Is Dispensable for Self-Renewal and Maintenance of Pluripotency in *Cyrano* KO Murine iPSCs(A) Schematic overview of the generation of murine *Cyrano* KO iPSCs by CRISPR/Cas9.(B) Graphical representation of three gRNAs (A, C, D) up- and downstream of the first exon of *Cyrano*. Primers used for PCR and sequencing are depicted as gray arrows, which amplify fragments of 800 bp in wild-type (WT) and 500 bp (using gRNA C and D) or 300 bp (using gRNA A and D) after CRISPR/Cas9 excision.(C) Verification of *Cyrano* KO via PCR. Unmodified cells were loaded as control (WT).(D) Example of Sanger sequencing results of clone CD 3 compared with WT *Cyrano* sequence. gRNA sequences are highlighted in green and purple with PAM sequences in gray, the sequence of the first exon is depicted in blue letters.(E and G) Relative expression levels in KO and unmodified cells (WT). Expression levels were measured by qPCR, mean ± SD of three independent experiments are shown, unpaired t test was performed for statistical analysis.(F) Representative images Oct4-EGFP expression and alkaline phosphatase staining of KO and unmodified cells (WT). iPSCs were cultured on feeder cells. Scale bar, 100 μm.

Based on a previous report linking *Cyrano* to pluripotency maintenance ([@bib20]), *Cyrano* KO iPSCs were analyzed for their pluripotency. The morphology of the cells appeared regular for iPSCs and the expression of pOCT4-EGFP showed no differences. In addition, the expression of alkaline phosphatase was not altered in *Cyrano* KO iPSCs compared with wild-type iPSCs ([Figure 2](#fig2){ref-type="fig"}F). The mRNA expression levels of *Nanog*, *Sox2*, and *Klf4* did not change in response to the loss of *Cyrano* ([Figure 2](#fig2){ref-type="fig"}G). Thus, our data demonstrate that *Cyrano* is not required for pluripotency in murine iPSCs.

Knockdown of *Cyrano* Does Not Interfere with Pluripotency in Human iPSCs {#sec2.3}
-------------------------------------------------------------------------

We next set out to investigate the role of *Cyrano* in human iPSCs. In contrast to the genetic KO approach in murine iPSCs, a CRISPRi system ([@bib17]) was used for inducible, highly efficient *Cyrano* knockdown (KD) ([Figure 3](#fig3){ref-type="fig"}A). Five different gRNAs, located around 150 bp up- and downstream of the transcription start site were designed, cloned into pgRNA-CKB, and nucleofected into CRISPRi iPSCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Bulk RNA expression analysis after dCas9 induction by doxycycline showed a significant downregulation of *Cyrano* for gRNA3 ([Figure S2](#mmc1){ref-type="supplementary-material"}B). After clonal expansion, 21 colonies were treated with doxycycline to shut down *Cyrano* expression, which did not result in morphological abnormalities. Four clones were selected for further analyses based on their strong repression of *Cyrano* ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The nearly complete ablation of *Cyrano* was verified by RNA FISH. Specific *Cyrano* signals were comparable in control cells (no doxycycline or no gRNA), whereas hardly any signal was detected in *Cyrano* KD cells after doxycycline treatment ([Figure 3](#fig3){ref-type="fig"}B).Figure 3KD of *Cyrano* with CRISPRi Approach Has No Impact on the Pluripotency of Human iPSCs(A) Schematic overview of the generation of inducible *Cyrano* KD human iPSCs using a CRISPRi approach.(B) Representative RNA FISH images stained with a *Cyrano*-specific probe in unmodified cells (CRISPRi) and one clone, with and without doxycycline (doxy) treatment. Nuclei were stained with DAPI. Scale bar, 5 μm.(C) Expression of *Cyrano*, *NANOG*, and *SOX2* after doxy treatment in the monoclonal population. Expression levels were measured by qRT-PCR, mean ± SD of three independent experiments are shown, unpaired t test was performed for statistical analysis.(D) Representative images of alkaline phosphatase staining of one KD clone with and without doxy treatment. Scale bar, 500 μm.(E) Flow cytometry analysis of SSEA4 and TRA1-60 of one clone. Isotype controls (light gray, filled) and unstained cells (dark gray line) were used as controls. Representative plots with mean ± SD of three independent experiments are depicted.(F) Fluorescence immunocytochemistry of NANOG, OCT4, and SOX2 was performed in *Cyrano* KD cells after doxy treatment. Scale bar, 100 μm.(G) Expression levels were measured by qRT-PCR, mean ± SD of three independent experiments, unpaired t test was performed for statistical analysis.(H) miR-7-5p was overexpressed in CRISPRi cells. Expression levels were measured by qRT-PCR, mean ± SD of three independent experiments, unpaired t test was performed for statistical analysis.(I) Volcano plot depicting the results of the RNA sequencing of *Cyrano* KD clone with and without doxy treatment of three experiments. Cut off criteria −1 \< log2(FC) \> 1, q \> 2. IPA network analysis.(J) RNA-seq tracks of CRISPRi 1II E12 with and without doxy.(K) Normalized read counts using DEseq2 of pluripotency-related and *Cyrano*-related genes.

To exclude doxycycline-specific effects, CRISPRi iPSCs without a gRNA were treated with doxycycline. No effects were observed with regard to growth dynamics, expression of pluripotency markers, or alkaline phosphatase staining ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2G).

Similar to the observation in murine iPSCs, the expression levels of *NANOG* and *SOX2* were unchanged after doxycycline-induced *Cyrano* KD ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}A). Furthermore, neither the alkaline phosphatase staining, nor the morphology of the cells showed any changes after *Cyrano* KD ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}B). The proliferation dynamics were also unaffected by the loss of *Cyrano* ([Figure S3](#mmc1){ref-type="supplementary-material"}C). The pluripotency markers SSEA4 and TRA1-60 were analyzed by flow cytometry, and NANOG, OCT4, and SOX2 by immunohistochemistry. These markers did not respond to loss of *Cyrano* ([Figures 3](#fig3){ref-type="fig"}E, 3F, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E). Since *Cyrano* was shown to act on miR-7-5p in murine ESCs, which in turn represses *Nanog* and *Itga9*, it was therefore suggested to influence pluripotency and cell adhesion ([@bib20]). We checked the expression of miR-7-5p, its proposed target *ITGA9*, and *GATA6* as a negatively regulated target of *NANOG*, and saw that silencing *Cyrano* significantly increased only miR-7-5p levels, while *ITGA9* and *GATA6* remained unaffected ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}F). In addition, iPSC treatment with miR-7-5p mimics had no consequences on *NANOG* (a suggested direct target of miR-7) or on *SOX2* expression ([Figure 3](#fig3){ref-type="fig"}H). Consequently, alkaline phosphatase staining after miR-7 overexpression was indifferent from mimic controls ([Figure S3](#mmc1){ref-type="supplementary-material"}G).

Loss of *Cyrano* Only Moderately Affects the Global Transcriptome {#sec2.4}
-----------------------------------------------------------------

Transcriptome analysis in human iPSCs with and without doxycycline treatment, i.e., in the presence and absence of *Cyrano,* led to differential expression of only 50 genes: 34 genes were up- and 16 downregulated (−1\<log2(FC) \> 1, p \< 0.01) ([Figures 3](#fig3){ref-type="fig"}I and [S4](#mmc1){ref-type="supplementary-material"}A). Using Ingenuity Pathway Analysis (IPA), downregulated genes are linked to the "cancer, cellular development, cellular growth and proliferation" network while upregulated genes are part of the "cell cycle, cell death and survival, gene expression," or "nervous system development and function, neurological disease, organ morphology" networks ([Figure 3](#fig3){ref-type="fig"}I). As shown in the RNA sequencing (RNA-seq) read mapping in a genome browser, *Cyrano* is nearly absent after doxycycline treatment. This had no effect on the neighboring genes *CHP1* and *OIP5*, indicating that off-target effects in *cis* can be ruled out ([Figures 3](#fig3){ref-type="fig"}J and [S4](#mmc1){ref-type="supplementary-material"}B). [Figure 3](#fig3){ref-type="fig"}K shows normalized RNA-seq read-count tables for genes related to pluripotency or connected to *Cyrano* based on literature research (more genes in [Figure S4](#mmc1){ref-type="supplementary-material"}C). None of them were significantly dysregulated after *Cyrano* KD except for orthodenticle homeobox 2 (*OTX2*), which is a transcription factor in brain development ([@bib3]). In line with higher levels of miR-7 after *Cyrano* KD ([Figure 3](#fig3){ref-type="fig"}G), some known miR-7 targets (IGFS8, SLC8A3) ([@bib1]) were downregulated, but none have been linked to pluripotency. The RNA-seq data were validated by qRT-PCR measurements ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Finally, to further demonstrate that *Cyrano* is dispensable for pluripotency, we performed a trilineage differentiation assay. Importantly, loss of *Cyrano* did not influence the potential of human iPSC to differentiate into the three different germ layers ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}E).Figure 4Silencing of *Cyrano* Does Not Influence the Differentiation Potential of Human iPSCs or Pluripotency of Human ESCs(A) Differentiation of iPSCs in the presence and absence of *Cyrano* to the three germ layers with subsequent immunofluorescence staining. Scale bar, 100 μm.(B) Gene expression of *Cyrano*, *NANOG*, and *SOX2* was analyzed by qRT-PCR, mean ± SD of three independent experiments, unpaired t test was performed for statistical analysis.(C) Flow cytometry analysis of SSEA4 and TRA1-60 after *Cyrano* silencing in human ESCs. Isotype controls (filled gray) and unstained cells (dark gray line) were used as controls.

Inhibition of *Cyrano* in Human ESCs by siRNA Has No Effect on Pluripotency {#sec2.5}
---------------------------------------------------------------------------

Despite large similarities of ESCs and iPSCs in expression patterns and chromatin modifications, there are also certain differences in gene expression and methylation profiles ([@bib6]). To test whether *Cyrano* is specifically required for the maintenance of pluripotency in human ESCs, we used an siRNA approach to silence *Cyrano* in these cells. *NANOG* and *SOX2* remained unchanged after silencing ([Figure 4](#fig4){ref-type="fig"}B) and the expression of SSEA4 and TRA1-60 did not change after *Cyrano* modulation ([Figure 4](#fig4){ref-type="fig"}C).

Discussion {#sec3}
==========

Here, we report that the highly conserved lncRNA *Cyrano* is enriched in PSCs which prompted us to investigate its functional role pluripotency. We used a dual gRNA CRISPR/Cas9 approach to generate a *Cyrano* KO in murine iPSCs, which did not result in adverse effects on pluripotency. This was in marked contrast to a simultaneously published report suggesting that *Cyrano* is essential for pluripotency in murine ESCs ([@bib20]). To have a more clinically translatable platform and to also strengthen our own data with a different approach, we used CRISPRi in human iPSCs for a robust KD of *Cyrano.* As a third model, we used human ESCs in which *Cyrano* was silenced with specific siRNAs. Both approaches confirmed the data from murine iPSCs, showing that *Cyrano* has no overt effect on pluripotency in stem cells from different species. As mentioned above, this is in contrast to previously published data suggesting that *Cyrano* derepresses *Nanog* by sponging miR-7-5p. The two main differences between the studies were: firstly, Smith et al. investigated murine ESCs grown in potentially less-stringent stem cell culture conditions that may favor differentiation upon *Cyrano* repression. Nevertheless, when seeding human ESCs at low density, which can be considered a less-stringent condition, no effect after siRNA *Cyrano* treatment was observed. Secondly, [@bib20] used commercially available small hairpin RNAs (shRNAs) for *Cyrano* KD. Since the shRNA sequences used in this study were not accessible, we were unable to further investigate this discrepancy. Of note, *Cyrano* was also found as a candidate in an RNAi screen for pluripotency-related lncRNAs in murine ESCs that also used shRNA technology ([@bib16]). Nevertheless, constraints on different approaches for loss-off-function studies were recently described, in particular, the comparison of screenings using CRISPR/Cas9 KO and shRNA-mediated KD showed weak correlations ([@bib18]). Moreover, the comparison of two different RNAi technologies showed poor reproducibility ([@bib5]). CRISPR technology has gained more popularity in the last years and outperformed RNAi approaches with less noise and off-target effects ([@bib8]). Hence, the readouts after modulation of transcript expression have to be validated carefully. Accordingly, we tested different approaches and cell types (mouse iPSCs, human iPSCs, and ESCs), which all showed the same effects. Thus, it is unlikely that our results are based on off-target or approach-dependent effects. It should be noted that, although unlikely given the high conservation of *Cyrano*, the previously described effects of shRNA-mediated KD of *Cyrano* may be unique to murine ESCs. But it is also unlikely that both shRNAs used by Smith et al. would show the same off-target effects, which is supported by their data showing that overexpression of miR-7-5p exhibits the same phenotype as *Cyrano* KD. Thus, there exists a currently unknown factor to explain the discrepancy between both studies.

We further investigated the suggested downstream mechanism via regulation of miR-7-5p. In line with previous reports, we found an upregulation of miR-7-5p after *Cyrano* inhibition. However, there was no evidence that miR-7-5p affects pluripotency in our systems as demonstrated in experiments with miR-7-5p mimics.

*Cyrano* was first described to be important for zebrafish embryogenesis and brain morphogenesis ([@bib22]), which goes along with the proposed role in self-renewal and maintenance of pluripotency of murine ESCs ([@bib20]). In contrast to the study in zebrafish, it was recently shown that a genetic KO of *Cyrano* in fish did not influence embryogenesis, viability, or fertility. The lack of reproducibility of the zebrafish experiments is based on off-target effects of the two different morpholinos that were used to inhibit *Cyrano* ([@bib10]). In addition, *Cyrano* KO mice do not show defects in embryogenesis, viability, or fertility ([@bib14]), which one would expect if *Cyrano* was essential for the maintenance of PSCs.

Finally, global transcriptomic analysis revealed that loss of *Cyrano* has only very moderate effects in PSCs that are not related to know pluripotency factors. Moreover, despite the absence of *Cyrano*, human iPSCs can be readily differentiated into the three germ layers which require the iPSCs to be truly pluripotent.

In summary, contradictory to previous data, we did not detect any changes in the pluripotency of murine and human iPSCs and human ESCs after *Cyrano* inhibition. Our different approaches to silence *Cyrano* in PSCs are highly consistent, firmly demonstrating that *Cyrano* is not regulating pluripotency. Nonetheless, the high degree of conservation and the high expression in PSCs assume an important cellular function of *Cyrano* for whose study we generated state-of-the-art *in vitro* tools.

Experimental Procedures {#sec4}
=======================

Detailed methods are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Murine iPSC Culture and Generation {#sec4.1}
----------------------------------

Murine iPSCs have been reprogrammed from OG2 mice expressing EGFP under the control of an Oct3/4 promoter ([@bib12]). The murine iPSCs were grown on irradiated mitotic inactive mouse embryonic fibroblasts.

To knock out the *Cyrano* gene in iPSCs, the dual gRNA CRISPR/Cas9 approach was used ([@bib11]). The first exon of *Cyrano* was excised with two gRNAs knocking out both murine transcripts.

Human iPSC Culture and Generation {#sec4.2}
---------------------------------

CRISPRi iPSCs ([@bib17]) were cultured on Matrigel Growth Factor Reduced (Corning) in mTesR (STEMCELL Technologies) and passaged when confluent with Accutase (STEMCELL Technologies) in mTeSR supplemented with 10 μM Y-27632 2HCI (Selleckchem).

The gRNA design, cloning, and nucleofection were performed as described previously ([@bib17]). For KD, induction cells were treated with 2 μM doxycycline for at least 3 days.

Human ESC Culture {#sec4.3}
-----------------

MIXL1-GFP human ESC ([@bib7]) were cultured on Geltrex (Thermo Fisher Scientific) in homebrewed E8 medium and passaged with Accutase (Gibco), seeded in 10 μM Y-27632 (Tocris). Cells came from a conventional feeder-based culture, expanded on Geltrex for two passages before being used for experiments.

Gene Expression {#sec4.4}
---------------

Total RNA of cultured cells was isolated using peqGOLD TriFast (VWR Life Science, Radnor, PA, USA) according to the manufacturer\'s instructions. RNA was DNase treated using RNase-free DNase set (QIAGEN), and 100 to 1,000 ng were reverse transcribed using Biozym cDNA synthesis kit.

To analyze miRNA expression levels 100 ng RNA was reverse transcribed using a iScript select cDNA synthesis kit (Bio-Rad) and specific TaqMan probes (hsa-miR-7-5p ID 005723_mat and RNU48 ID 001006, Thermo Fisher Scientific).

Real-time quantitative PCR was performed in CFX384 Touch Real-Time PCR Detection System (Bio-Rad) or QuantStudio 7 Flex System (Applied Biosystems). For mRNA and lncRNA expression analysis, iQ SYBR Green Supermix (Bio-Rad) was used and Absolute Blue qPCR Mix (Thermo Fisher Scientific) was used for miRNA expression analysis.

Absolute Quantification {#sec4.5}
-----------------------

The copy number of *Cyrano* was quantified by qPCR and a plasmid standard curve as described previously ([@bib9]).

Growth Curve {#sec4.6}
------------

iPSCs (1 × 10^5^) were seeded on Matrigel, and the following day doxycycline treatment was started and cells were counted for 5 consecutive days with Countess II (Invitrogen).

Alkaline Phosphatase Staining {#sec4.7}
-----------------------------

The iPSCs were stained with the Alkaline Phosphatase Detection Kit (Millipore) according to the manufacturer\'s guidelines. Images were acquired with an Eclipse Ti-U fluorescence microscope (Nikon) and NIS Elements BR 3.26 (Nikon) software.

Flow Cytometry {#sec4.8}
--------------

For flow cytometry, cells were harvested, stained, then washed. Measurement was performed at Guava easyCite 5 flow cytometer (Millipore) and data analyzed with FlowJo (BD).

Human ESCs were fixed and permeabilized with FIX&PERM kit 1000 (Nordic MUbio). Staining was performed as described above.

Immunocytochemistry {#sec4.9}
-------------------

iPSCs were washed, permeabilized, and incubated with primary and secondary antibodies.

RNA FISH {#sec4.10}
--------

RNA FISH was performed using a ViewRNA Cell plus Assay (Thermo Fisher Scientific) according to the manufacturer\'s guidelines in Nunc Lab-Tek eight-well chamber slides (Merck) with a specific *Cyrano* probe (ID VA1-3020478-VCP, Thermo Fisher Scientific). Images were acquired using a Leica SP8 confocal microscope and LAS X (Leica) software.

Trilineage Differentiation {#sec4.11}
--------------------------

Differentiation was performed using a STEMdiff Trilineage Differentiation Kit (STEMCELL Technologies) according to manufacturer\'s guidelines.

Transfection of siRNA {#sec4.12}
---------------------

Downregulation was achieved by transfecting 200 nM siRNAs (Eurofins) with Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s guidelines.

PCR {#sec4.13}
---

PCR was performed using a HotStar Mastermix Kit (QIAGEN) according to the manufacturer\'s guidelines in 10 μL reaction. PCR products were resolved by agarose gel electrophoresis (0.8%--1.2% agarose gel in 1× TAE).

Sanger Sequencing {#sec4.14}
-----------------

To verify sequences, DNA bands were cut from an agarose gel and DNA was extracted via the QIAquick Gel Extraction Kit (QIAGEN). Five to 10 ng/μL PCR product or 50--100 ng/μL plasmid DNA were brought to 15 μL volume premixed with 2 μL primer (10 μM) and sent to Eurofins for sequencing.

RNA-Seq {#sec4.15}
-------

RNA was isolated using a miRNeasy mini kit (QIAGEN) according to the manufacturer\'s guidelines. Sample preparation and data processing are described in [Supplemental Information](#app1){ref-type="fn"}.

Statistics {#sec4.16}
----------

Statistical analyses were performed using an unpaired Student\'s t test. The results shown were obtained by at least three measurements (mean ± standard deviation \[SD\]). Statistical analysis was carried out using GraphPad Prism 8.

Data and Code Availability {#sec4.17}
--------------------------

RNA-seq data (GEO: [GSE150421](ncbi-geo:GSE150421){#intref0010}) are available in the Gene Expression Omnibus.
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